- First Online:
Prasugrel (Efient®) is a potent, selective and irreversible inhibitor of adenosine diphosphate (ADP)-mediated platelet aggregation that is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) [comprising unstable angina pectoris/non-ST-segment-elevation myocardial infarction (unstable angina/NSTEMI) and ST-segment-elevation myocardial infarction (STEMI)] undergoing percutaneous coronary intervention (PCI).
Oral prasugrel provides rapid, potent inhibition of platelet aggregation and is an effective antiplatelet agent for the management of patients with ACS who are undergoing PCI. In these patients, prasugrel was associated with a significantly lower incidence of ischaemic events than clopidogrel, and was particularly effective in specific subgroups of patients, such as those with diabetes mellitus. However, the efficacy of prasugrel was offset by a higher risk of bleeding than clopidogrel, with patients aged ≥75 years, those weighing <60 kg and those with a history of stroke or transient ischaemic attack at the greatest risk. A lower dose of prasugrel in patients aged ≥75 years and those weighing <60 kg may help to minimize the bleeding risk, although more data are needed to establish this; prasugrel is contraindicated in patients with a history of stroke or transient ischaemic attack. Thus, prasugrel provides a new option for the management of patients with ACS who are undergoing PCI; the risk-benefit ratio should be carefully assessed before intensive antiplatelet therapy with prasugrel is initiated.
Prasugrel is a potent thienopyridine antiplatelet agent that selectively and irreversibly inhibits ADP-induced platelet aggregation mediated by the P2Y12 receptor. Prasugrel is a prodrug that must first undergo biotransformation to its active metabolite via cytochrome P450-mediated hepatic metabolism. In healthy volunteers, patients undergoing PCI and patients with coronary artery disease, greater and more rapid inhibition of platelet aggregation was seen with prasugrel than with clopidogrel. Inhibition of platelet aggregation occurred ≤1 hour after administration of prasugrel. Metabolism of prasugrel to the active metabolite occurred rapidly with the peak plasma concentrations of the active metabolite reached within ≈30 minutes. Formation of the active metabolite was more rapid and extensive with prasugrel than with clopidogrel, potentially explaining its more rapid onset and greater degree of platelet aggregation inhibition.
In a large, randomized, double-blind, multicentre, phase III trial known as the TRITON-Thrombolysis In Myocardial Infarction (TIMI) 38, prasugrel was more effective than clopidogrel in the prevention of ischaemic events during long-term follow-up for up to 15 months in patients with ACS who were undergoing scheduled PCI, as well as during the periprocedural period (first 3 days of treatment). The risk of death from cardiovascular causes, nonfatal myocardial infarction and nonfatal stroke (composite primary endpoint) in patients with unstable angina, NSTEMI or STEMI was significantly lower with prasugrel than with clopidogrel. Landmark analyses demonstrated this effect was apparent both during the first 3 days of treatment and from day 3 until the end of the trial.
Prasugrel was also significantly more effective than clopidogrel in reducing ischaemic events in various patient subpopulations, including patients who had received at least one coronary stent and patients undergoing PCI for STEMI, while a more pronounced effect was observed in patients with a history of diabetes. The incidence of recurring cardiovascular events were also significantly lower in prasugrel recipients than in clopidogrel recipients.
Bleeding events were the most frequently reported adverse events associated with prasugrel treatment. The incidence of TIMI major bleeding events not related to coronary artery bypass grafting (CABG) was significantly higher with prasugrel than clopidogrel, including the incidence of life-threatening bleeding and fatal bleeding events. Combined non-CABG-related TIMI major and minor bleeding events were also more frequent in prasugrel recipients than in clopidogrel recipients, while a greater percentage of prasugrel than clopidogrel recipients discontinued treatment because of adverse events related to bleeding.
Post hocanalyses showed that patients aged ≥75 years and those weighing <60 kg experienced no net benefit, and those with a history of cerebrovascular events experienced net harm and an increased risk of intracranial bleeding compared with clopidogrel.
The frequency of serious adverse events not related to bleeding was generally similar between prasugrel and clopidogrel recipients.
Unable to display preview. Download preview PDF.
- 8.Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007 Aug 14; 116(7): e148–304PubMedCrossRefGoogle Scholar
- 9.Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation 2008 Jan 15; 117(2): 296–329PubMedCrossRefGoogle Scholar
- 10.King 3rd SB, Smith Jr SC, Hirshfeld Jr JW, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008 Jan 15; 117(2): 261–95PubMedCrossRefGoogle Scholar
- 11.Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005 Apr; 26(8): 804–47Google Scholar
- 18.Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J Thromb Haemost 2007 Jul; 5(7): 1545–51PubMedCrossRefGoogle Scholar
- 25.Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008 Jan; 29(1): 21–30PubMedCrossRefGoogle Scholar
- 26.Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008 Dec 9; 52(24): 1968–77PubMedCrossRefGoogle Scholar
- 27.Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007 Dec 18; 116(25): 2923–32PubMedCrossRefGoogle Scholar
- 30.Sanofi-Aventis. Plavix (75mg & 300mg film coated tablets) summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/9483/SPC/Plavix+(sanofi-aventis)/ [Accessed 2009 Jun 12]
- 31.Eli Lilly and Company Limited. Efient (5mg & 10mg film coated tablets) summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/21504/SPC/Efient+5mg+&+10mg+film+coated+tablets/ [Accessed 2009 Mar 16]
- 33.European Medicines Agency. Assessment report for Efient [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Efient/H-984-en6.pdf [Accessed 2009 Jun 15]
- 35.Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009 May 19; 119(19): 2553–60Google Scholar
- 37.Small DS, Kothare PA, Yuen ES, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects [abstract no. PII-47]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S56–7Google Scholar
- 42.Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006 Oct; 152(4): 627–35PubMedCrossRefGoogle Scholar
- 43.Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005 Jun 28; 111(25): 3366–73PubMedCrossRefGoogle Scholar
- 44.Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology task force on clinical data standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001 Dec; 38(7): 2114–30PubMedGoogle Scholar
- 45.Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008 May 27; 51(21): 2028–33PubMedCrossRefGoogle Scholar
- 46.Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009 Feb 28; 373(9665): 723–31PubMedCrossRefGoogle Scholar
- 47.Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008 Apr 19; 371(9621): 1353–63PubMedCrossRefGoogle Scholar
- 48.Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008 Oct 14; 118(16): 1626–36PubMedCrossRefGoogle Scholar
- 50.Morrow DA, Wiviott SD, White HD. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: thrombolysis in myocardial infarction 38 an application of the classification system from the universal definition of myocardial infarction. Circulation 2009 Jun; 119(21): 2758–64PubMedCrossRefGoogle Scholar
- 52.Salazar DE, Ernest CS, Wrishko RE, et al. Relationship between exposure to the prasugrel active metabolite with TIMI major/minor bleeding in TRITON-TIMI 38 [abstract no. 4001]. Circulation 2008 Oct; 118 Suppl. 2: S815Google Scholar
- 53.Dalby AJ, Wiviott SD, Murphy SA, et al. The Influence of the arterial access site and its management on bleeding events in acute coronary syndromes in TRITON — TIMI 38. Circulation 2008 Oct; 118 Suppl. 2: S638Google Scholar
- 54.Wiviott SD, Ruff CT, Antman EM, et al. Regional safety and efficacy of prasugrel compared to clopidogrel: a TRITON-TIMI 38 analysis [abstract no. 4588]. Circulation 2008 Oct; 118 Suppl. 2: S917Google Scholar
- 55.Effient™ (prasugrel) [US prescribing information]. Indianapolis: Eli Lilly and Company, 2009 [online]. Available from URL: http://pi.lilly.com/us/effient.pdf [Accessed 2009 Jul 13]
- 57.Eli Lilly and Company. European Commission approves Efient® (prasugrel) for patients with acute coronary syndrome undergoing PCI [media release]. 2009 Feb 23 [online]. Available from URL: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=366955 [Accessed 2009 Apr 14]
- 64.Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004 Jul 24; 364(9431): 331–7PubMedCrossRefGoogle Scholar
- 67.Kaul S, Shah PK, Diamond GA, et al. Validity of the combined efficacy plus safety composite endpoint (net clinical benefit) in TRITON-TIMI 38 [abstract no. 4015]. Circulation 2008 Oct; 118 Suppl. 2: S819Google Scholar
- 68.Kaul S, Shah PK, Diamond GA. Weighted composite end-point analysis of TRITON-TIMI 38: disconnect between analytical equivalence and clinical importance [abstract no. 4587]. Circulation 2008 Oct; 118 Suppl. 2: S916Google Scholar
- 71.Eli Lilly and Company. A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS) [ClinicalTrials.gov identifier NCT00699998]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Jun 17]